ReviewClinical and translational science2012
The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients.
Review in Clinical and translational science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.The Cochrane database of systematic reviews · 2015Pooled it
- Article
- D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review.ERJ open research · 2020Review
- Genistein has the function of alleviating and treating disseminated intravascular coagulation caused by lipopolysaccharide.Journal of natural medicines · 2018Article
- Pharmacological inhibitors of TRPV4 channels reduce cytokine production, restore endothelial function and increase survival in septic mice.Scientific reports · 2016Article
- Biology of sepsis: its relevance to pediatric nephrology.Pediatric nephrology (Berlin, Germany) · 2014Review
- Evidence of Disseminated Intravascular Coagulation in a Porcine Model Following Radiation Exposure.Life sciences in space research · 2014Article
- Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study.Experimental and therapeutic medicine · 2014Article
- Is disseminated intravascular coagulation the major cause of mortality from radiation at relatively low whole body doses?Radiation research · 2013Article
- Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view.Mediators of inflammation · 2013Review
- Renal artery thrombosis secondary to sepsis-induced disseminated intravascular coagulation in acute pyelonephritis.Kidney research and clinical practice · 2012Article
- Biomarkers of sepsis.Critical reviews in clinical laboratory sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disseminated intravascular coagulation (DIC) profoundly increases the morbidity and mortality of patients who have sepsis. Both laboratory and clinical research advanced the understanding of the biology and pathophysiology of DIC. This, in turn, gave rise to improved therapies and patient outcomes. Beginning with a stimulus causing disruption of vascular integrity, cytokines and chemokines cause activation of systemic coagulation and inflammation. Seemingly paradoxically, the interplay between coagulation and inflammation also inhibits endogenous anticoagulants, fibrinolytics, and antiinflammatory pathways. The earliest documented and best-studied microbial cause of DIC is the lipopolysaccharide endotoxin of Gram-negative bacteria. Extensive microvascular thrombi emerge in the systemic vasculature due to dysregulation of coagulation. The result of this unrestrained, widespread small vessel thromboses multiorgan system failure. Consumption of platelets and coagulation factors during this process can lead to an elevated risk of hemorrhage. The management of these patients with simultaneous hemorrhage and thrombosis is complex and challenging. Definitive treatment of DIC, and attenuation of end-organ damage, requires control of the inciting cause. Currently, activated protein C is the only approved therapy in the United States for sepsis complicated by DIC. Further research is needed in this area to improve clinical outcomes for patients with sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.